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Background
The search for novel immunogens capable of eliciting
neutralizing antibodies (NAbs) against HIV-1 is compli-
cated by its high mutation rate which modifies envelope
glycoproteins (Env) during the course of HIV-1 infection
and drives NAb escape. However Env from transmission
strains due to absence of NAb selection pressure could be
antigenically distinct from late stage Env and hence profil-
ing them would help identify novel vaccine immunogens
capable of eliciting NAbs.
Methods
Blood samples were collected from 36 HIV-1 patients of
pre-seroconversion (PSC) cohort based on p24 antigen,
viral load, ELISA and western blot assays. Five samples
(within Fiebig stage IV) were chosen to generate a panel of
28 gp160 clones. These were genotyped for amino acid
changes in potential N-linked glycosylation (PNG) sites,
length of variable loops (VL) and binding sites of recep-
tors and neutralizing monoclonal antibodies (mAbs).
These were phenotyped for Env mediated entry utilizing
CD4, CCR5 and CXCR4. Recombinant gp140 clones were
constructed to produce soluble gp140. Purified gp140 Env
were assessed by ELISA for binding affinities to CD4, b12,
2G12, 2F5 and 17b+sCD4.
Results
The number of PNG sites and length of V4 VL were lower,
with fewer changes in CD4, co-receptors and mAbs bind-
ing sites compared with AD8 and pNL4.3 reference
sequences. 10(36%) PSC Env clones mediated entry using
all 3 receptors. Recombinant gp140 Env clones were con-
structed, stably expressed and soluble oligomers purified.
Affinities studies by ELISA for 5 selected Env in compari-
son with AD8, showed 4 Env to possess high binding
affinities to CD4, b12, 2F5, 2G12, 17b+sCD4 and 2 Env
to 2G12.
Conclusion
Characterization studies of PSC Env indicates that early
Env have fewer modifications unlike late stage Env, signi-
fying better exposure of conserved functional domains
and neutralization sensitive epitopes required to elicit
NAbs. The immunogenicity of PSC Env are currently
being assessed in animal models.
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